WESTLAKE VILLAGE, Calif., Aug. 5, 2024 /PRNewswire/ -- Turn Therapeutics, a pharmaceutical and medical device company focused on immunology, advanced wound care, and dermatology, announced today positive data results of GX-03 in a biomarker study intended to measure its immunological inhibitory effects during eczema induction.
Turn Therapeutics Atopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo
Turn Therapeutics invites public investment for expansion of flagship wound formula into eczema, toenail fungus
Agreement provides MIMEDX with exclusive rights to Turn’s PermaFusion® proprietary antimicrobial intellectual property (IP), accelerating the product development pipeline for wound and surgical...
LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, a biotechnology company specializing in advanced wound care and infection control, today announced the results of its Phase 2B, placebo controlled trial of Hexagen Antimicrobial Ointment in treating mild to moderate infected COVID-19 patients. This double-blinded study enrolled 80 people across three sites in Panama to evaluate safety and efficacy of Hexagen Antimicrobial as an early intervention against COVID-19. Specifically, the study investigated intranasal use of FDA-cleared Hexagen immediately post-positive PCR test as a means to reduce disease duration, as well as the safety of consistent intranasal use of Hexagen over 5 and 10 days. Efficacy results have confirmed in-vitro virucidal data, while safety results have confirmed in-vivo biocompatibility data for use on mucous membranes.